Chimeric Therapeutics Ltd (ASX:CHM, OTC:CHMMF) has received a research and development (R&D) tax incentive refund of $4,497,886 under the Australian Government’s R&D Tax Incentive program.
The R&D Tax Incentive provides companies undertaking eligible activities with a refundable tax offset of up to 43.5%. The refund recognises Chimeric’s R&D activities during the 2025 financial year.
The clinical-stage cell therapy company, focused on developing cell therapies for patients with cancer, has a diversified portfolio that includes first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies, with four clinical-stage programs across multiple oncology indications.
CHM CDH17
CHM CDH17 is a first-in-class, third-generation CDH17 CAR T therapy invented at the University of Pennsylvania (Penn) in the laboratory of Dr Xianxin Hua, professor in the Department of Cancer Biology at the Abramson Family Cancer Research Institute. Preclinical data published in Nature Cancer in March 2022 demonstrated complete eradication of tumours in seven cancer types in mice. CHM CDH17 is currently being studied in a Phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours initiated in 2024.
CHM CORE-NK
CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the completed Phase 1A clinical trial, published in March 2022, demonstrated safety and efficacy in blood cancers and solid tumours. Based on the activity observed, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has also commenced development of next-generation NK and CAR NK assets.
CHM CLTX
CHM CLTX is a novel CAR T therapy in development for patients with solid tumours. CLTX CAR T is currently being evaluated in a Phase 1B clinical trial in recurrent/progressive glioblastoma. Positive preliminary data from the investigator-initiated Phase 1A trial in glioblastoma were announced in October 2023.